Medicago receives contribution from NRC-IRAP for seasonal flu vaccine program



    QUEBEC CITY, July 3 /CNW/ - Medicago Inc. (TSX-V: MDG) today announced it
has been awarded a non-refundable contribution of up to $279,700 from Canada's
National Research Council Industrial Research Assistance Program ("NRC-IRAP")
to support the development of the Company's seasonal influenza Virus-Like
Particles (VLP) vaccine program. Medicago is developing a seasonal vaccine
based on its proprietary VLP manufacturing technology, which has the potential
to offer speed and cost advantages over competitive technologies.
    "This contribution is a continuation of our ongoing relationship since
2001 with Canada's National Research Council," said Andy Sheldon, President
and CEO of Medicago. "The development of a seasonal influenza vaccine
candidate is in-line with our strategy to expand our product portfolio and
continue to leverage our technology platform to deliver highly effective and
affordable vaccines. We would like to thank NRC for their continued guidance
and contributions."

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

    Forward Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    The TSX Venture Exchange assumes no responsibility for the content or
    accuracy of this press release

    %SEDAR: 00023641EF




For further information:

For further information: Contact: Medicago, Inc., Andy Sheldon,
President and CEO, (418) 658-9393; Investor relations: The Equicom Group Inc.,
Arianna Vanin, (514) 844-4680, avanin@equicomgroup.com

Organization Profile

Medicago Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890